Navigation Links
Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
Date:3/30/2011

GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for Xeomin® (incobotulinumtoxinA).  Merz expects that this unique billing code, which will become effective on April 1, 2011, will help simplify the billing and reimbursement process for prescribers of XEOMIN.

The U.S. Food and Drug Administration (FDA) approved XEOMIN on July 30, 2010, for the treatment of adults with cervical dystonia (CD), to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naive and previously treated patients, and blepharospasm in adults who have been previously treated with Botox® (onabotulinumtoxinA).

“Merz is pleased to report broad interest in XEOMIN at the provider level as well as strong reimbursement coverage by private and public payors,” said Jack Britts, President and CEO of Merz Pharmaceuticals, LLC.  “We are confident that the addition of this unique billing code will assist in streamlining billing and reimbursement for XEOMIN.”

As permanent national codes are issued annually, CMS awards Q-codes when it identifies a need to provide a unique code in order to reduce billing confusion before the next national update on January 1 of the following year.  Merz has applied for and anticipates receiving a permanent J-code for XEOMIN on January 2, 2012.

For providers and payors, utilizing a unique Q-code is in most circumstances administratively identical to billing under a permanent J-code. The availability of this unique code, Q2040, means that in most instances XEOMIN will no longer be billed under a miscellaneous code.  

“This is a significant milestone for the dystonia community and we are so pleased that CMS granted this product-specific code for XEOMIN,” said Janet Hieshetter, Executive Director of the Dystonia Medical Research Foundation (DMRF). “This news follows a recent meeting that several representatives from the dystonia advocacy community had with government officials late last year about the importance of ensuring access to all available treatment options, and we’re all quite grateful that our voices were heard.”

Merz also recently introduced two comprehensive programs to provide patients with financial assistance for XEOMIN. The XEOMIN Patient Co-payment Program is easy-to-use and offers eligible patients assistance for their actual out-of-pocket costs for therapeutic treatment with XEOMIN. Eligible treatment-related costs may include the cost of XEOMIN, associated guidance therapy and related administration fees.

Additionally, the XEOMIN Patient Assistance Program provides XEOMIN at no cost to eligible patients who are experiencing financial hardship, do not have third-party drug coverage, and who are not eligible for government-funded drug programs.

For more information about reimbursement support and financial assistance programs for XEOMIN, visit www.Xeomin.com or call 1-888-4-XEOMIN (1-888-493-6646). Dedicated support representatives are available from 8 a.m. until 8 p.m. (EST), Monday through Friday.

About XEOMINIn nature, Clostridium botulinum produces the toxin in association with ancillary accessory proteins. Manufacturers utilize this naturally occurring protein complex to produce therapeutic botulinum toxin products. XEOMIN (incobotulinumtoxinA) is manufactured using a proprietary process that isolates the therapeutic component and eliminates accessory proteins.

More than 84,000 patients have been treated with XEOMIN worldwide since 2005.  The U.S. is the 20th country to approve XEOMIN for the treatment of cervical dystonia and blepharospasm.

XEOMIN is the only botulinum toxin that does not require refrigeration prior to reconstitution. XEOMIN is available in 50-unit and 100-unit vials, which Merz believes may allow for more precise billing and reduce wastage.

IMPORTANT SAFETY INFORMATIONWARNING: Distant Spread of Toxin EffectPostmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.CONTRAINDICATIONSXEOMIN is contraindicated in patients with a known hypersensitivity to the active substance botulinum toxin type A or to any of the components in the formulation and in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

  • The potency units of XEOMIN are not interchangeable with other preparations of botulinum toxin products.  Therefore, units of biological activity of XEOMIN cannot be compared to or converted into units of any other botulinum toxin products.
  • Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted.
  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [See Boxed Warning]. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. These reactions can occur within hours to weeks after injection with botulinum toxin.
  • Cervical Dystonia: Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.
  • Blepharospasm:  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.

  • ADVERSE REACTIONSCervical Dystonia:  The most commonly observed adverse reactions (incidence greater than or equal to 10% of patients and twice the rate of placebo) for XEOMIN 120 Units and XEOMIN 240 Units, respectively, were: dysphagia (13%, 18%), neck pain (7%, 15%), muscle weakness (7%, 11%), and musculoskeletal pain (7%, 4%).

    Blepharospasm: The most common adverse reactions (incidence greater than or equal to 10% of patients and twice the rate of placebo) for XEOMIN were eyelid ptosis (19%), dry mouth (16%), visual impairment (12%), diarrhea (8%), and headache (7%).

    DRUG INTERACTIONSConcomitant treatment of XEOMIN and aminoglycoside antibiotics, spectinomycin, or other agents that interfere with neuromuscular transmission (e.g., tubocurarine-like agents), or muscle relaxants, should be observed closely because the effect of XEOMIN may be potentiated.

    USE IN PREGNANCYPregnancy Category C: There are no adequate and well-controlled studies in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Please see full Prescribing Information for XEOMIN, including Boxed WARNING, available at www.XEOMIN.com.

    About Merz Merz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Dermatology, and Podiatry.

    With a 102 year heritage, the Merz Group is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine. Global research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances

    XEOMIN is a registered trademark of MerzPharma GmbH & Co KGaA.  

    Botox® is a registered trademark of Allergan, Inc.


    '/>"/>

    SOURCE Merz Pharmaceuticals, LLC
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
    2. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
    3. Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
    4. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
    5. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
    6. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
    7. Inovio Pharmaceuticals to Present at Scientific Conferences
    8. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
    9. JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
    10. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
    11. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
    (Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
    (Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
    Breaking Medicine Technology:
    (Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted ... and 40-Hour courses from now until November 30, 2017 to assist with the clean-up ... prices to all businesses and government agencies – whether or not they will be ...
    (Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
    (Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
    (Date:9/19/2017)... ... September 19, 2017 , ... ... Brazilian jiu-jitsu community have raised more than $15,000 in just a couple of ... professional submission grappling matches and world-class instructor seminars, organizers expect to double those ...
    (Date:9/19/2017)... ... ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. To date, ... million in resolved debt for its clients. , Credit card debt, unpaid hospital bills, ... debt settled by the company. With more than a decade of combined service to ...
    Breaking Medicine News(10 mins):